Q4 FY2026 · ended Jun 30, 2026 · Revenue $-86,000 · Filed Sep 25, 2026
Incannex Healthcare Inc. (IXHL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $86,000 and a net loss of $2.5 million. Free cash flow was $3.4 million. As of Jun 30, 2026 it held $67.7 million in cash and investments and $96,000 in total debt.
Revenue
$-86,000
Net income
$-2.49M
+92.1% vs year-ago quarter
Operating cash flow
$3.37M
+327.7% vs year-ago quarter
Free cash flow
$3.37M
+327.6% vs year-ago quarter
EPS
$-0.20
+98.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
12.54M
-96.4% vs year-ago quarter
Net cash
$67.61M
Q4 FY2026
Operating margin
6036.0%
Q4 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IXHL (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Norwest Nsw
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1873875
- Former names
- Incannex Healthcare Ltd (until Nov 29, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | -$86,000 | — | — | — | — |
| Operating income | -$5.2M | -$4.0M | -$7.0M | -$6.8M | -$7.5M |
| Net income | -$2.5M | -$3.9M | -$6.5M | -$6.4M | -$31.6M |
| Diluted EPS | -$0.20 | -$0.35 | -$0.02 | -$0.02 | -$11.41 |
| Operating cash flow | $3.4M | -$2.5M | -$4.6M | -$9.2M | -$1.5M |
| Free cash flow | $3.4M | -$2.5M | -$4.6M | -$9.2M | -$1.5M |
| Total assets | $73.0M | $80.3M | $75.0M | $78.7M | $20.4M |
| Total liabilities | $5.6M | $5.0M | $1.6M | $1.7M | $7.1M |
| Stockholders' equity | $67.4M | $75.2M | $73.4M | $77.0M | $13.4M |
| Cash and investments | $67.7M | $74.5M | $68.9M | $73.3M | $15.0M |
| Total debt | $96,000 | $114,000 | $163,000 | $211,000 | $258,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 28, 2026 | Jun 30, 2026 |
| 10-K | Annual report | Sep 25, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 25, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 23, 2026 | Jul 23, 2026 |
All 266 Incannex Healthcare Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.